Adjuvant paclitaxel and trastuzumab for node-negative HER2- positive breast cancer

K
Kathy Miller, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

No Description Available

Description

No Description Available

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Breast Cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Female
Updated on 20 Nov 2022. Study ID: 1010002438 (0802-11)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center